Oncology

Test projects which agent will work best against particular tumors.

Melanoma incidence increased 250% in children, adolescents and young adults since 1973.

Gene mutations found in some patients provide hope for new and existing treatments.

A pair of large RNA classes associated with a protein that may play a role in cancer progression.

Uncertainty persists in how collagen influences cancer cell behavior.

Nearly 1 in 4 patients treated in childhood for Hodgkin's lymphoma developed a second type of cancer within 30 years.

Treatment advances have caused significant progress in survivorship.

Protein that helps cancer cells avoid death offers promising target.

Smokers face high risk of disease recurrence after completing treatment.

Investigational drug will move to phase 3 studies.

Treatment prior to surgery leads to fewer side effects and better quality of life.

Top stories of the week on Specialty Pharmacy Times from May 18 to May 22.

Acute lymphoblastic leukemia accounts for nearly 25% of cancer diagnoses in children under 15 years of age.

New approach seeks to lessen resistance to cancer drugs while mitigating adverse events.

Anti-PDL1 agent with standard chemotherapy combination will now move to multiple phase 3 studies.

Study finds benefits from reduced absenteeism and improved workplace productivity.

Economic downturn associated with cancer mortality.

Blood test predicts which patients will respond to interferon.

Black men more likely to be diagnosed with breast cancer at a younger age than white men.

Excess medical expenses, employment disability, and a drop in production at work common in cancer survivors.

Study warns that drug reviewers don't look at long term survival of patients.

Particles protected antigen from premature destruction and prompted the immune system to attack cancer cells.

Age and weight found to play a role in side effects.

Kjel Jonhson, PharmD, Vice President of Global Oncology for IMS Health, discusses changes in store for the care of cancer patients over the next decade.

Mass spectrometry reveals all proteins that repair damaged cancer DNA.

Targeting gene mutations causes stress that damages cancer cell DNA.

Treating immune-suppressing cells allows for destruction of tumors.

Study finds chronic hepatitis C has a limited impact on mortality unless the patient has other severe comorbidities.

Despite advances in pain management and palliative care, intractable cancer pain remains a significant clinical, social, and financial burden in treating the oncologic population.

A look back at the top stories on Specialty Pharmacy Times from May 4 to May 8.